🇺🇸 FDA
Patent

US 10046028

Methods and compositions for modulating PD1

granted A61KA61K38/1709A61K40/11

Quick answer

US patent 10046028 (Methods and compositions for modulating PD1) held by Sangamo Therapeutics, Inc. expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K38/1709, A61K40/11, A61K40/22, A61K40/416